Skip to main content
MS-DRG 018 · Pre-MDC · Medical

MS-DRG 018: Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: IPPS Table 5 (MS-DRG weights): v44 FY2027 (final rule + CN3) (effective October 1, 2026); MS-DRG Definitions Manual: v44 (effective October 1, 2026). Next CMS release: FY2028 final rule (August 2027), effective October 1, 2027; an April 1 interim grouper update when CMS issues one for the IPPS Table 5 (MS-DRG weights); the FY2028 grouper, effective October 1, 2027 for the MS-DRG Definitions Manual.

Key facts for DRG 018

FY2027 relative weight
45.1464
Higher than 100% of all MS-DRGs
Change vs FY2026
+4.6%
FY2026 weight 43.1828
Geometric mean LOS
11.4 days
Arithmetic mean 13.3 days
MDC
Pre-MDC
Pre-MDC (transplants, tracheostomy, ECMO)
Severity level
single severity level
National unadjusted operating payment
$309,162.55
Weight × $6,848.00 FY2027 standardized amount; capital adds $24,376.80
Transfer policy
Not a transfer DRG

TL;DR

MS-DRG 018 is a medical group in the Pre-MDC set (transplants, tracheostomy and ECMO), with no CC/MCC severity split. CMS assigns it a FY2027 relative weight of 45.1464 with a geometric mean length of stay of 11.4 days and an arithmetic mean of 13.3. Its weight moved up 4.6% from FY2026 (43.1828). That weight is in the top 1% of all MS-DRGs. The v44 Definitions Manual assigns it through 8 t-cell immunotherapy (operating room procedures) codes and 34 t-cell immunotherapy (non-operating room procedures) codes.

What changed from FY2026 to FY2027

CMS recalibrates every MS-DRG weight annually from the prior year's MedPAR claims. For DRG 018 the FY2027 relative weight is 45.1464 against 43.1828 in FY2026, a rise of 4.55%, which exceeds the 2% threshold worth re-checking in contract models.

FY2026 versus FY2027 payment factors for MS-DRG 018
MetricFY2026FY2027Change
Relative weight43.182845.1464+1.9636
Geometric mean LOS (days)12.411.4-1.0
Arithmetic mean LOS (days)14.713.3-1.4
Weights shown are the FY2027 final values after the 10% cap on year-over-year reductions where applicable.

CC and MCC family

DRG 018 stands alone: CMS does not split this base group by CC or MCC severity, so complication documentation does not move the assignment, although it still affects quality and risk-adjustment reporting.

National unadjusted payment for DRG 018

Multiplying the FY2027 relative weight (45.1464) by the national rates in IPPS Tables 1A and 1D, as corrected by notice CMS-1849-CN3, gives the base amounts below. This group has no CC/MCC sibling, so the amount does not change with secondary-diagnosis capture.

FY2027 national unadjusted IPPS payment for MS-DRG 018
ComponentNational rateDRG 018
Operating (labor and nonlabor share)$4,519.68 + $2,328.32 = $6,848.00$309,162.55
Capital (federal rate)$539.95$24,376.80
Operating plus capital$333,539.35
Assumes the full annual update (the hospital submitted quality data and is a meaningful EHR user). A hospital with a reduced update starts from $299,491.74 to $306,744.96 for the operating portion of this DRG.

These are national, unadjusted figures, not what a given hospital is paid. The labor share is multiplied by the hospital's wage index (Table 1A applies when the wage index is above 1.0 and Table 1B otherwise), and teaching (IME), disproportionate share (DSH), outlier, transfer and new-technology add-on rules then change the amount for each stay. Use the figures to compare groups and to size a documentation finding, not to forecast a remittance; the DRG payment calculator applies a hospital's own wage index and teaching and DSH factors to DRG 018.

New for FY2027: codes that group to DRG 018

IPPS Tables 6A and 6B assign 2 new ICD-10-PCS codes to DRG 018 from October 1, 2026. Encoders and edit tables that still run the v43 code set reject these codes or group them elsewhere, so check them first when a FY2027 discharge in this DRG fails an edit. The FY2027 ICD-10 code-change report lists every addition and deletion with its CC level and MS-DRGs.

New FY2027 ICD-10-PCS codes that group to DRG 018
ICD-10-PCSDescriptionO.R.Effective
XW0331BIntroduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11No2026-04-01
XW0431BIntroduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11No2026-04-01

Grouper logic (v44 Definitions Manual)

T-cell Immunotherapy (Operating Room Procedures): 8 ICD-10-PCS codes in this DRG's assignment logic.

T-cell Immunotherapy (Operating Room Procedures) codes in the logic for DRG 018 (sample)
ICD-10-PCS codeDescription
XHR0XGAReplacement of Head and Neck Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10
XHR1XGAReplacement of Chest Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10
XHR2XGAReplacement of Abdomen Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10
XHR3XGAReplacement of Back Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10
XHR4XGAReplacement of Right Upper Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10
XHR5XGAReplacement of Left Upper Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10
XHR6XGAReplacement of Right Lower Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10
XHR7XGAReplacement of Left Lower Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10

T-cell Immunotherapy (Non-Operating Room Procedures): 34 ICD-10-PCS codes in this DRG's assignment logic; the first 12 are shown.

T-cell Immunotherapy (Non-Operating Room Procedures) codes in the logic for DRG 018 (sample)
ICD-10-PCS codeDescription
XW0331BIntroduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW03368Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW03378Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0338AIntroduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033A7Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033BAIntroduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033C7Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033FAIntroduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033FBIntroduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW033G7Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033J7Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

Documentation and denial exposure

As a medical DRG, assignment depends on the principal diagnosis sequenced from the attending's documentation; a secondary condition sequenced first, or a symptom code in place of the confirmed diagnosis, changes the MDC or the DRG. Because this family has no severity split, review risk concentrates on medical-necessity of the admission itself and on the two-midnight benchmark. Typical inpatient denial codes for this group: CARC 16 (claim lacks information needed to group the stay), CARC 50 (the admission or procedure is judged not medically necessary), CARC 97 (a service is bundled into the DRG payment).

For teams evaluating QuickIntell software

Evaluate a documentation and coding workflow for DRG 018

Explore QuickCode for qualified coder review and documentation clarification, or QuickScribe for clinician-reviewed visit documentation. Confirm inpatient scope, the supported grouper version and reviewer responsibilities during evaluation. This public reference is not a production grouper and does not determine a claim's reimbursement.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — DRG 018

What is MS-DRG 018?

MS-DRG 018 is "Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies", a medical Medicare Severity Diagnosis-Related Group in the Pre-MDC set (transplants, tracheostomy and ECMO). Medicare pays inpatient stays grouped here at the hospital's base rate multiplied by the DRG relative weight.

What is the FY2027 relative weight for DRG 018?

The FY2027 relative weight is 45.1464 (IPPS final rule Table 5, effective October 1, 2026). In FY2026 it was 43.1828, a change of +4.6%.

What is the Medicare base payment for MS-DRG 018?

$309,162.55 for operating costs plus $24,376.80 for capital, $333,539.35 together, at the FY2027 national rates: weight 45.1464 times the $6,848.00 operating standardized amount and the $539.95 capital rate (IPPS Tables 1A and 1D as corrected by CMS-1849-CN3). The hospital's wage index, IME, DSH, outlier and transfer adjustments change what a given stay is paid.

What is the average length of stay for DRG 018?

CMS reports a geometric mean length of stay of 11.4 days and an arithmetic mean of 13.3 days for FY2027. The geometric mean is used for transfer-payment calculations.

What documentation supports the severity level of DRG 018?

DRG 018 has no CC or MCC sibling, so secondary-diagnosis capture does not change the group or its 45.1464 weight. Review effort belongs instead on the principal diagnosis sequencing and the 8 procedure codes that place the stay in this group, and on medical necessity of the inpatient admission itself under the two-midnight benchmark against a 11.4-day geometric mean stay, which is where denials for single-severity groups concentrate.

Which codes group to DRG 018?

The v44 Definitions Manual lists 8 t-cell immunotherapy (operating room procedures) codes and 34 t-cell immunotherapy (non-operating room procedures) codes for this group. Examples from the t-cell immunotherapy (operating room procedures) list, XHR6XGA (Replacement of Right Lower Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10); XHR7XGA (Replacement of Left Lower Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10); and from the t-cell immunotherapy (non-operating room procedures) list, XW033H7 (Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7); XW033J7 (Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7).

Is DRG 018 a post-acute transfer DRG?

No. DRG 018 is not on the FY2027 post-acute care transfer list, so the transfer per-diem policy does not apply to it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from the CMS IPPS FY2027 final rule (Table 5) and the v44 ICD-10 MS-DRG Definitions Manual. Relative weights are national factors; actual payment depends on each hospital's wage-adjusted base rate, add-ons, outliers and transfer adjustments. Nothing here is legal, clinical or billing advice; verify grouping against your encoder and the published CMS files.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.